Drugs Xagena
The FDA ( Food and Drug Administration ) has granted accelerated approval to Opdivo ( Nivolumab ), a new treatment for patients with unresectable ( cannot be removed by surgery ) or metastatic ( advan ...
The FDA ( Food and Drug Administration ) has approved Opdivo ( Nivolumab ) injection, for intravenous use, for the treatment of patients with metastatic squamous non-small cell lung cancer ( NSCLC ) w ...
Opdivo, a PD-1 checkpoint inhibitor approved in Europe, for both first-line and previously-treated advanced melanoma patients The European Commission has approved Opdivo ( Nivolumab ), a PD-1 immu ...
The FDA ( Food and Drug Administration ) has granted accelerated approval for Keytruda ( Pembrolizumab ) to treat patients with advanced ( metastatic ) non-small cell lung cancer ( NSCLC ) whose disea ...
The FDA ( Food and Drug Administration ) has approved Opdivo ( Nivolumab ) to treat patients with advanced ( metastatic ) non-small cell lung cancer whose disease progressed during or after Platinum-b ...
The FDA ( Food and Drug Administration ) has approved Opdivo ( Nivolumab ) to treat patients with advanced ( metastatic ) renal cell carcinoma, who have received a certain type of prior therapy. Op ...
The European Commission has approved Nivolumab BMS ( Opdivo ) for the treatment of locally advanced or metastatic squamous ( SQ ) non-small cell lung cancer ( NSCLC ) after prior chemotherapy. This ...
The FDA ( Food and Drug Administration ) has approved a new second-generation lung cancer treatment that can help many patients in their battle against the disease. Lung cancer patients got another ro ...
The FDA ( Food and Drug Administration ) has approved Opdivo ( Nivolumab ) injection, for intravenous use for the treatment of patients with locally advanced or metastatic urothelial carcinoma ( mUC ) ...
The European Commission ( EC ) has approved Opdivo ( Nivolumab ) for the treatment of locally advanced unresectable or metastatic urothelial carcinoma ( mUC ) in adults after failure of prior Platinum ...
Opdivo ( Nivolumab ) 1 mg/kg plus Yervoy ( Ipilimumab ) 3 mg/kg ( injections for intravenous use ) was approved by the U.S. Food and Drug Administration ( FDA ) to treat hepatocellular carcinoma ( HCC ...
Opdivo ( Nivolumab ) 3 mg/kg plus Yervoy ( Ipilimumab ) 1 mg/kg ( injections for intravenous use ) was approved by the U.S. Food and Drug Administration ( FDA ) for the first-line treatment of adult p ...
Opdivo ( Nivolumab ) was approved by the U.S. Food and Drug Administration ( FDA ) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma ...
The U.S. Food and Drug Administration ( FDA ) has approved Opdivo ( Nivolumab ) 360 mg every three weeks plus Yervoy ( Ipilimumab ) 1 mg/kg every six weeks ( injections for intravenous use ) for the f ...
The European Commission ( EC ) has approved Opdivo ( Nivolumab ) plus Yervoy ( Ipilimumab ) with two cycles of Platinum-based chemotherapy for the first-line treatment of adult patients with metastati ...
The FDA ( U.S. Food and Drug Administration ) has approved Opdivo ( Nivolumab ) 240 mg injection for intravenous use every two weeks or 480 mg every four weeks in combination with CaboMetyx ( Cabozant ...
The U.S. Food and Drug Administration ( FDA ) ha approved Opdivo ( Nivolumab ) 240 mg every two weeks or 480 mg every four weeks ( injection for intravenous use ) for the adjuvant treatment of patient ...
The U.S. Food and Drug Administration ( FDA ) has approved Opdivo ( Nivolumab ) 360 mg ( injection for intravenous use ) in combination with Platinum-doublet chemotherapy every three weeks for three c ...
The European Commission ( EC ) has approved Opdivo ( Nivolumab ) for the adjuvant treatment of adults with muscle-invasive urothelial carcinoma with tumor cell PD-L1 expression 1% or more who are at a ...
The U. S. Food and Drug Administration ( FDA ) has approved Opdivo ( Nivolumab ), for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck ( SCCHN ) with ...
On march 4, 2022, the US Food and Drug Administration (FDA) approved Nivolumab ( Opdivo ) plus Platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non–small-cell lu ...
